Skip to main content
Premium Trial:

Request an Annual Quote

Bio-Rad Posts Big Q2 Revenue, Profit Gains on DiaMed Contribution

NEW YORK (GenomeWeb News) – Bio-Rad Laboratories reported after the close of the market on Tuesday that its second-quarter revenues rose 33.4 percent and its net income increased 68.9 percent due largely to the contribution of DiaMed Holding, a developer of blood-typing reagents and screening tools that Bio-Rad purchased last October for $400 million.
The Hercules, Calif.-based life sciences tools and diagnostics maker brought in revenues of $452.4 million for the three-month period ended June 30, compared to revenues of $339.1 million in the second quarter of 2007. Bio-Rad said that excluding the contribution from DiaMed, its revenues rose 14.7 percent year over year, or 6.6 percent on a currency-neutral basis.
DiaMed contributed $65 million in revenues for the quarter, while currency translation accounted for $27 million, Bio-Rad President and CEO Norman Schwartx noted during the firm's second-quarter conference call.
Sales for its life sciences segment increased 10.7 percent, or 3.2 percent excluding currency effects, to $161.6 million. The firm credited sales of reagents and assay panels for its Bio-Plex suspension array system as part of the reason for the revenue gains. However, it noted that capital equipment sales declined slightly, “reflecting a general softness in the market resulting from reduced spending by both academic and bio-pharmaceutical customers.”
Bio-Rad’s clinical diagnostics segment reported sales of $287.4 million for the quarter, up 51.4 percent from the comparable period in 2007. Excluding DiaMed, sales for the segment rose 17.9 percent, or 9.4 percent on a currency-neutral basis. The firm said growth came across all product lines, particularly quality control, diabetes, and autoimmune products.
Bio-Rad posted a profit of $43.4 million, or $1.58 per share, compared to $25.7 million, or $.95 per share, last year.
Its R&D spending rose 21 percent to $42.1 million from $34.8 million, while its SG&A costs climbed 22.6 percent to $146.6 million from $119.6 million year over year.
Bio-Rad finished the quarter with $183.6 million in cash and cash equivalents.
In early Wednesday trade on the American Stock Exchange, shares of Bio-Rad were up 10.5 percent at $101.83.
The Scan

International Team Proposes Checklist for Returning Genomic Research Results

Researchers in the European Journal of Human Genetics present a checklist to guide the return of genomic research results to study participants.

Study Presents New Insights Into How Cancer Cells Overcome Telomere Shortening

Researchers report in Nucleic Acids Research that ATRX-deficient cancer cells have increased activity of the alternative lengthening of telomeres pathway.

Researchers Link Telomere Length With Alzheimer's Disease

Within UK Biobank participants, longer leukocyte telomere length is associated with a reduced risk of dementia, according to a new study in PLOS One.

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.